Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

被引：1

作者：

Richardson, Paul G. ^{[1
,2
]}

Perrot, Aurore ^{[3
]}

San-Miguel, Jesus ^{[4
]}

Beksac, Meral ^{[5
]}

Spicka, Ivan ^{[6
,7
]}

Leleu, Xavier ^{[8
,9
]}

Schjesvold, Fredrik ^{[10
,11
]}

Moreau, Philippe ^{[12
]}

Dimopoulos, Meletios A. ^{[13
]}

Huang, Jeffrey S. Y. ^{[14
]}

Minarik, Jiri ^{[15
,16
]}

Cavo, Michele ^{[17
]}

Prince, H. Miles ^{[18
]}

Mace, Sandrine ^{[19
]}

Malinge, Laure ^{[20
]}

Dubin, Franck ^{[19
]}

Morisse, Mony ^{[21
]}

Anderson, Kenneth C. ^{[1
]}

机构：

[1] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA

[3] Toulouse Univ, Inst Canc, Dept Hematol, Toulouse, France

[4] Clin Univ Navarra, IDISNA, CIBERONC, CIMA, Pamplona, Spain

[5] Ankara Univ, Dept Hematol, Ankara, Turkey

[6] Charles Univ Prague, Gen Fac Hosp, Prague, Czech Republic

[7] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[8] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

[9] CIC Inserm 1402, Poitiers, France

[10] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[11] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[12] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[13] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[14] Natl Taiwan Univ Hosp, Dept Hematol, Taipei, Taiwan

[15] Palacky Univ, Fac Hosp, Dept Hematooncol, Olomouc, Czech Republic

[16] Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic

[17] IRCCS Azienda Osped Univ Bologna, Ist Ematol Sergnoli, Bologna, Italy

[18] Univ Melbourne, Epworth Healthcare, Immunol & Mol Oncol, Melbourne, Vic, Australia

[19] Sanofi, Vitry Sur Seine, France

[20] Sanofi, Boulogne, France

[21] Sanofi, Cambridge, MA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159710

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[2] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Attal, Michel
Richardson, Paul G.
Rajkumar, S. Vincent
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn P.
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth C.
LANCET, 2019, 394 (10214): : 2096 - 2107
[3] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C.
LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
[4] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study (vol 23, pg 416, 2022)
Richardson, P. G.
Perrot, A.
San-Miguel, J.
LANCET ONCOLOGY, 2022, 23 (04): : E161 - E161
[5] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (vol 394, pg 2096, 2019)
Attal, M.
Richardson, P. G.
Rajkumar, S., V
LANCET, 2019, 394 (10214): : 2072 - 2072
[6] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study (vol 23, pg 416, 2022)
Richardson, P. G.
Perrot, A.
San-Miguel, J.
LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
[7] Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus F.
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Sy.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
Van de Velde, Helgi
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Schjesvold, Fredrik
Richardson, Paul G.
Facon, Thierry
Alegre, Adrian
Spencer, Andrew
Jurczyszyn, Artur
Sunami, Kazutaka
Frenzel, Laurent
Min, Chang-Ki
Guillonneau, Sophie
Lin, Peggy L.
Le-Guennec, Solenn
Campana, Frank
van de Velde, Helgi
Bensfia, Samira
Bringhen, Sara
HAEMATOLOGICA, 2021, 106 (04) : 1182 - 1187
[9] Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Schjesvold, Fredrik
Bringhen, Sara
G. Richardson, Paul
Perrot, Aurore
Leleu, Xavier
Moreau, Philippe
A. Dimopoulos, Meletios
Hulin, Cyrille
Tekle, Christina
Foster, Meredith C.
Poole, Elizabeth M.
van de Velde, Helgi
Facon, Thierry
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : E423 - E427
[10] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2017, 130 (10) : 1189 - 1197

← 1 2 3 4 5 →